Table 3.
Effect of PRP concentrations and extender types on post-thaw sperm quality (mean ± SEM)
| Extender | PRP (%) | N | Progressive motility (%) | Viability (%) | Abnormality (%) |
|---|---|---|---|---|---|
| OptiXcell® A | 0% | 48 | 46.50 ± 0.73c | 75.50 ± 0.62c | 18.67 ± 0.29a |
| 5% | 48 | 49.17 ± 0.60b | 78.67 ± 0.29b | 15.17 ± 0.48b | |
| 10% | 48 | 52.34 ± 0.96a | 80.83 ± 0.75a | 9.67 ± 0.49c | |
| 15% | 48 | 51.17 ± 0.30a | 80.17 ± 0.62ab | 10.83 ± 0.38c | |
| Tris egg yolk-based B | 0% | 48 | 43.67 ± 0.53c | 73.17 ± 0.40b | 21.17 ± 0.48a |
| 5% | 48 | 45.16 ± 0.58bc | 74.50 ± 0.55b | 18.93 ± 0.70b | |
| 10% | 48 | 47.25 ± 0.84a | 76.67 ± 0.88a | 14.17 ± 0.36c | |
| 15% | 48 | 45.67 ± 0.52ab | 76.00 ± 0.41a | 15.66 ± 0.22c |
N = 48 ejaculates. Within columns, values with different superscripts differ significantly for each parameter (P < 0.05)
Within the same column, means bearing a, b, and c differ among PRP concentrations (0%, 5%, 10% and 15%) within the same extender (OptiXcell® or Tris egg yolk-based). A and B differ between extender types (OptiXcell® or Tris egg yolk-based), at the same PRP concentrations (0%, 5%, 10% and 15%). PRP, Platelet-rich plasma